Manchester Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Manchester Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,813	Closed	-$44K	–	515
2017 Q3	$44K	Hold	3,813	–	–	0.01%	353
2017 Q2	$37K	Hold	3,813	–	–	0.01%	372
2017 Q1	$92K	Hold	3,813	–	–	0.01%	288
2016 Q4	$122K	Hold	3,813	–	–	0.02%	246
2016 Q3	$191K	Hold	3,813	–	–	0.03%	195
2016 Q2	$162K	Hold	3,813	–	–	0.02%	223
2016 Q1	$251K	Hold	3,813	–	–	0.03%	173
2015 Q4	$237K	Hold	3,813	–	–	0.03%	194
2015 Q3	$255K	Hold	3,813	–	–	0.04%	169
2015 Q2	$371K	Hold	3,813	–	–	0.06%	145
2015 Q1	$356K	Hold	3,813	–	–	0.06%	144
2014 Q4	$339K	Hold	3,813	–	–	0.04%	239
2014 Q3	$263K	Hold	3,813	–	–	0.04%	281
2014 Q2	$219K	Hold	3,813	–	–	0.03%	347
2014 Q1	$151K	Hold	3,813	–	–	0.02%	414
2013 Q4	$160K	Buy	+3,813	New	+$111K	0.02%	382

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Manchester Capital Management's MACK Position: Q4 2017 in Review

Manchester Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2017, closing a stake of 3,813 shares — an estimated $44K sold.

Manchester Capital Management first reported a position in MACK in Q4 2013 and held it in 16 quarters. The position peaked at $371K in Q2 2015. 78 funds tracked by Wall St. Rank hold MACK as of Q4 2017.

Manchester Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Manchester Capital Management sold 3,813 Merrimack Pharmaceuticals, Inc. shares in Q4 2017, an estimated $44K.
Manchester Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2013 and held it in 16 quarters.
Manchester Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $371K in Q2 2015.
78 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2017.

Based on Manchester Capital Management's 13F filing for Q4 2017, filed 8 Feb 2018.